Companies › CNS Pharmaceuticals
1 active drug program in 1 registered trial: 1 Phase 2; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Berubicin DNA topoisomerase II inhibitor | TOP2A, TOP2B | Phase 2 | Glioblastoma Multiforme, Adult | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04762069 | Berubicin | Phase 2 | Glioblastoma Multiforme, Adult | Oncology | Apr 2026 |
Cash of $20m on 2026-06-30; operating cash outflow about $17m a year; runway about 14 months at that burn, to Sep 2027
Press releases filed as 8-K in the last year:
CEBIOTEX Targeted Therapy Technologies Allarity Therapeutics Processa Pharmaceuticals Moleculin Biotech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.